2016-07-05 13:35:26 UTC

AGA and Pfizer Inc. Call on Scientists to Offer New Approaches to IBD Research

Pfizer will fund three research grants to support innovative research projects related to IBD.

Contact: Rachel Shubert
media@gastro.org
301-272-1603

Bethesda, MD (July 5, 2016) — The AGA Research Foundation and Pfizer Inc. are teaming up to offer three research grants to support innovative research projects related to inflammatory bowel disease (IBD).

The new AGA-Pfizer Pilot Research Award in Inflammatory Bowel Disease will support pilot projects proposed by investigators interested in exploring new research directions in IBD. This award will provide non-salary funds for new investigators to help establish their research careers or, for established investigators, it will support pilot projects that represent new research directions.

“To continue to improve the diagnosis and treatment of IBD, we need innovative researchers with new approaches,” said Robert S. Sandler, MD, MPH, AGAF, chair of the AGA Research Foundation. “This kind of scientific exploration has the potential to make a tremendous impact on the future of health care. The AGA Research Foundation sincerely thanks Pfizer for its support and commitment to stimulating new lines of research.”

The AGA-Pfizer Pilot Research Award in Inflammatory Bowel Disease will provide a one-year grant of $30,000 to an investigator at any stage of his or her career to support a pilot research project related to IBD. Pfizer has committed to support one award each year for three years (three recipients total). Applicants interested in applying should visit the AGA website.

The deadline for applications is Jan. 13, 2017, with a funding date of July 1, 2017. The AGA Research Awards Panel will select recipients based on novelty, importance, feasibility, environment, institutional commitment and the overall likelihood that the project will lead to subsequent, more substantial grants.

IBD, which includes Crohn's disease and ulcerative colitis, impacts more than 5 million people worldwide. While researchers have made great strides in understanding IBD, additional work remains to better understand the causes of IBD and the most effective treatment options.

About the AGA Institute 

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization.www.gastro.org

Like AGA on Facebook. 
Join AGA on LinkedIn.
Follow us on Twitter @AmerGastroAssn
Check out our videos on YouTube.

About the AGA Research Foundation

The AGA Research Foundation, formerly known as the Foundation for Digestive Health and Nutrition, is the cornerstone of AGA’s effort to expand digestive disease research funding. Since 1984, the AGA, through its foundations, has provided more than $47 million in research grants to more than 870 scientists. The AGA Research Foundation serves as a bridge to the future of research in gastroenterology and hepatology by providing critical funding to advance the careers of young researchers between the end of training and the establishment of credentials that earn National Institutes of Health grants. Learn more about the AGA Research Foundation or make a contribution at www.gastro.org/foundation.

About Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn and like us on Facebook at Facebook.com/Pfizer.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

The Crohn's & Colitis Foundation and AGA are partnering on a new annual conference for health-care professionals and researchers. By joining the nation's leading IBD patient organization with the premier gastroenterological professional organization, this is the must-attend IBD conference, bringing state-of-the-art comprehensive care together with the latest research to advance prevention, treatment and cures for IBD patients.

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Recurrent Ileal Subocclusion Related to Multiple Polyps and Misdiagnosed as Crohn’s Disease

June 22, 2017

A 46-year-old woman presented with subacute symptoms preceding intestinal obstruction.